ArticleJournal of advanced research2026
Tumour-specific delivery of ω-conotoxin MVIIA via engineered Salmonella for safe anticancer therapy.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bacteria-releasing mucoadhesive sheet for localized delivery and penetrative therapy of gastrointestinal cancer.Materials today. Bio · 2026Article
- Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSolid tumours present a significant treatment challenge owing to the poor penetration of therapeutics into the tumour core. Bacteria offer a unique solution to this problem because they can selectively target tumours and proliferate within the tumour microenvironment.
methodsIn this study, we engineered Salmonella typhimurium to deliver MVIIA, a ω-conotoxin that inhibits N-type calcium channels. The engineered Salmonella strain was designed to efficiently secrete MVIIA via the flagellar type III secretion system (T3SS) under inducible control, ensuring tumour-specific delivery.
resultsMVIIA-secreting Salmonella significantly inhibited the proliferation of human and mouse colon cancer cell lines in vitro, with similar effects observed in other solid tumour models. Engineered bacteria selectively localise to tumour tissues in vivo, persist within the tumour microenvironment, and are rapidly cleared from non-tumour organs. In vivo delivery of MVIIA-secreting Salmonella in a colon cancer model effectively suppressed tumor cell growth, improved survival, reduced the expression of proliferation markers, and increased the expression of apoptosis markers. Consistent antitumor effects were also observed in breast cancer and melanoma models. Notably, no systemic toxicity was detected, indicating the safety of this approach.
conclusionsThese findings demonstrate the potential of MVIIA-secreting Salmonella spp. as a novel drug delivery platform to address the key limitations of conventional therapies. This strategy provides a foundation for advancing bacterial-mediated treatments in oncology, with broad applicability to various solid tumours and the potential for integration into combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.